<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40122811</article-id><article-id pub-id-type="pmc">PMC11929977</article-id>
<article-id pub-id-type="publisher-id">13921</article-id><article-id pub-id-type="doi">10.1186/s12885-025-13921-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Tenosynovial giant cell tumours of the foot and ankle: a retrospective single centre experience with surgical treatment of 34 cases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Scheele</surname><given-names>Christian</given-names></name><address><email>christian.b.scheele@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Harrasser</surname><given-names>Norbert</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beischl</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dammerer</surname><given-names>Dietmar</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lenze</surname><given-names>Ulrich</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Knebel</surname><given-names>Carolin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>von Eisenhart-Rothe</surname><given-names>R&#x000fc;diger</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lenze</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jc43x05</institution-id><institution-id institution-id-type="GRID">grid.15474.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0477 2438</institution-id><institution>Department of Orthopaedics and Sports Orthopaedics, </institution><institution>Technical University of Munich, Klinikum Rechts der Isar, </institution></institution-wrap>Ismaninger Str. 22, 81675 Munich, Germany </aff><aff id="Aff2"><label>2</label>Department of Orthopaedics and Traumatology, Krems University Hospital, Krems, 3500 Austria </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>530</elocation-id><history><date date-type="received"><day>17</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025, corrected publication 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Tenosynovial giant cell tumour (TGCT) is one of the most prevalent soft tissue tumours of the foot and ankle. Although typically benign, it can exhibit locally aggressive behaviour. This study aims to evaluate the distribution, surgical management, and recurrence rates of localized (L-TGCT) and diffuse (D-TGCT) forms of TGCT.</p></sec><sec><title>Methods</title><p id="Par2">A retrospective study of 34 TGCT cases in the foot and ankle treated surgically between 2010 and 2023 was conducted. Inclusion criteria required a histologically confirmed diagnosis and a minimum potential follow-up period of 18 months. Patient demographics, radiological findings, surgical approach and recurrence rates were evaluated.</p></sec><sec><title>Results</title><p id="Par3">Of 34 cases, 61.8% were L-TGCT and 38.2% were D-TGCT. L-TGCT had a significantly shorter duration of symptoms (median: 6 months) than D-TGCT (36 months, <italic>p</italic>&#x02009;=&#x02009;0.01) and affected significantly more females (76.2%; <italic>p</italic>&#x02009;=&#x02009;0.013). Nineteen cases were intraarticular, and 15 cases extraarticular manifestationsMacroscopically complete resection was achieved in 95.2% of L-TGCT cases and 69.2% of D-TGCT cases (<italic>p</italic>&#x02009;=&#x02009;0.037). The recurrence rate with limited follow-up was 26.7% for L-TGCT and 50.0% for D-TGCT (<italic>p</italic>&#x02009;=&#x02009;0.263). Time to recurrence was 7.0 months for L-TGCT and 12.0 months for D-TGCT (<italic>p</italic>&#x02009;=&#x02009;0.287). In 40% of these cases, therapeutic intervention was performed.</p></sec><sec><title>Conclusion</title><p id="Par4">In the foot and ankle, L-TGCT is more common in females, presents earlier after symptom onset, and has a higher rate of complete resection, whereas D-TGCT has a longer symptom duration and higher recurrence rates. It&#x02019;s important for orthopaedic surgeons to weigh surgical margins against functional results, as stable outcomes appear to be attainable even in cases of residual or recurrent tumours.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>TGCT</kwd><kwd>Tenosynovial giant cell tumour</kwd><kwd>PVNS</kwd><kwd>Pigmented villonodular synovitis</kwd><kwd>Soft-tissue tumour</kwd><kwd>Foot</kwd><kwd>Ankle</kwd></kwd-group><funding-group><award-group><funding-source><institution>Technische Universit&#x000e4;t M&#x000fc;nchen (1025)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Tenosynovial giant cell tumour (TGCT) is one of the most frequently occurring soft tissue tumours of the foot and ankle and was previously known as pigmented villonodular synovitis (PVNS) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Nevertheless, with an annual incidence of 1 per 1.8&#x000a0;million, it is a rare disease, affecting the synovium, tendon sheaths, and bursae of small and large joints, and generally occurring in the third to fifth decades of life [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. It typically presents as a monoarticular condition, with the foot and ankle region being the second most commonly affected area, accounting for up to 23% of cases, after the knee joint, which accounts for 53% [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par6">Two distinct types of TGCT exist, the localized (L-TGCT) and the diffuse TGCT (D-TGCT), which can occur intra- and extraarticular [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. These types exhibit different clinical presentations and prognosis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. The diagnosis of L-TGCT or D-TGCT is based on radiological and intraoperative findings.</p><p id="Par7">Although it is generally a benign process, TGCT can exhibit proliferative, locally aggressive behaviour, which may result in progressive joint degeneration by infiltrating bone and cartilage [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. The relative scarcity of TGCT cases in the foot and ankle often limited sample sizes in previous studies [<xref ref-type="bibr" rid="CR25">25</xref>]. The objective of this study is to present the experience of an orthopaedic tumour centre in the treatment of TGCT of the foot and ankle to further contribute to the understanding and clinical management of the disease.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design and patient selection</title><p id="Par8">This retrospective study was approved by the local ethics committee and included all patients with a histologically confirmed diagnosis of TGCT of the foot and ankle who were presented to our multidisciplinary tumour board between January 2010 and August 2023 and underwent surgical treatment at our institution. Patients were included if they had a histologically confirmed TGCT of the foot and ankle, underwent surgical resection at our institution, and had a minimum follow-up period of 18 months (February 2025).</p></sec><sec id="Sec4"><title>Patient characteristics and tumour classification</title><p id="Par9">Various patient characteristics were evaluated, including age, duration of complaints, symptoms, sex, side, BMI, and radiological tumour size. The type of TGCT (localised or diffuse), the presence of bone involvement and the anatomical location (intra- or extraarticular) were also analysed based on preoperative MRI imaging and surgical reports. For intraarticular manifestations, the joint from which the tumour originated was recorded. With regard to extraarticular TGCT, the anatomical classification proposed by Toepfer et al. [<xref ref-type="bibr" rid="CR2">2</xref>] was used, which distinguishes between the forefoot (phalanges), midfoot (metatarsals and small tarsus), hindfoot (talus and calcaneus), and ankle (distal tibia and fibula).</p></sec><sec id="Sec5"><title>Diagnosis and surgical treatment</title><p id="Par10">The diagnostic and therapeutic approach was assessed, including whether a primary biopsy was performed, the type of surgical procedure (open vs. arthroscopic), and the macroscopic resection status.</p></sec><sec id="Sec6"><title>Follow-up and outcome assessment</title><p id="Par11">The number and timing of radiological follow-up examinations were documented, along with corresponding findings (residual, recurrence, recurrence-free) and, if applicable, size progression (progressive, stable). All medical reports, digitised treatment documents, and available radiological examinations were analysed.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par12">Data were collected and analysed using Microsoft Excel 2016 (Microsoft, Richmond, WA) and DATAtab (DATAtab 2023: Online Statistics Calculator. DATAtab e.U. Graz, Austria). The Kolmogorov-Smirnov test was employed for the analytical testing of the normal distribution of metric variables. For comparison of normally distributed metric variables, the t-test for independent samples was utilized. Levene&#x02019;s test was conducted to assess equality of variance. In case of non-normally distributed metric variables, the Mann-Whitney U test was employed. The Chi2-test was conducted to examine associations between two categorical variables. To verify a balanced frequency distribution of a dichotomous variable, the binomial test was applied. The Kaplan-Meier curve was employed to analyse recurrence-free survival, with the log-rank test used to assess differences between groups. The significance level was set at <italic>p</italic>&#x02009;=&#x02009;0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par13">Of the 34 cases of TGCT in the foot and ankle, 23 occurred in female patients (67.6%) and 11 in male patients (32.4%). The left side was affected in 67.6% of cases, while the right side was involved in 32.4%. An overview of patient characteristics is presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Age, BMI, and tumor size followed a normal distribution (<italic>p</italic>&#x02009;=&#x02009;0.753, <italic>p</italic>&#x02009;=&#x02009;0.323, and <italic>p</italic>&#x02009;=&#x02009;0.246, respectively), whereas the duration of symptoms at initial presentation did not (<italic>p</italic>&#x02009;=&#x02009;0.016).</p><p id="Par14">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline and preoperative characteristics of the 34 patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">L-TGCT (<italic>n</italic>&#x02009;=&#x02009;21)</th><th align="left">D-TGCT (<italic>n</italic>&#x02009;=&#x02009;13)</th><th align="left">Total (<italic>n</italic>&#x02009;=&#x02009;34)</th></tr></thead><tbody><tr><td align="left">
<bold>Demographic Data</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Age (years, mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">32.2&#x02009;&#x000b1;&#x02009;17.5</td><td align="left">37.4&#x02009;&#x000b1;&#x02009;12.2</td><td align="left">34.2&#x02009;&#x000b1;&#x02009;15.7</td></tr><tr><td align="left">Sex (male/female)</td><td align="left">5/16 (23.8%/76.2%)</td><td align="left">6/7 (46.2%/53.8%)</td><td align="left">11/23 (32.4%/67.6%)</td></tr><tr><td align="left">Side (left/right)</td><td align="left">15/6 (71,4%/28,6%)</td><td align="left">8/5 (61,5%/38,5%)</td><td align="left">23/11 (67,6%/32,4%)</td></tr><tr><td align="left">BMI (kg/m&#x000b2;, mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">26.1&#x02009;&#x000b1;&#x02009;5.4</td><td align="left">28.1&#x02009;&#x000b1;&#x02009;7.5</td><td align="left">26.8&#x02009;&#x000b1;&#x02009;6.2</td></tr><tr><td align="left">
<bold>Symptoms &#x00026; Diagnosis</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Symptom duration (months, median [IQR])</td><td align="left">6.0 [1.0&#x02013;12.0]</td><td align="left">36.0 [29.3&#x02013;87.0]</td><td align="left">10.5 [1.8&#x02013;36.0]</td></tr><tr><td align="left">Pain only (%)</td><td align="left">11.1%</td><td align="left">7.7%</td><td align="left">9.7%</td></tr><tr><td align="left">Swelling only (%)</td><td align="left">11.1%</td><td align="left">15.4%</td><td align="left">12.9%</td></tr><tr><td align="left">Pain&#x02009;+&#x02009;Swelling (%)</td><td align="left">77.8%</td><td align="left">76.9%</td><td align="left">77.4%</td></tr><tr><td align="left">
<bold>Tumor Characteristics</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Tumour size (cm, mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">3.0&#x02009;&#x000b1;&#x02009;1.4</td><td align="left">3.8&#x02009;&#x000b1;&#x02009;2.1</td><td align="left">3.3&#x02009;&#x000b1;&#x02009;1.7</td></tr><tr><td align="left">Intraarticular cases (%)</td><td align="left">10 (47.6%)</td><td align="left">9 (69.2%)</td><td align="left">19 (55.9%)</td></tr><tr><td align="left">Extraarticular cases (%)</td><td align="left">11 (52.4%)</td><td align="left">4 (30.8%)</td><td align="left">15 (44.1%)</td></tr><tr><td align="left">Biopsy before resection (%)</td><td align="left">25.0%</td><td align="left">27.3%</td><td align="left">25.8%</td></tr></tbody></table></table-wrap>
</p><p id="Par15">At initial presentation, 9.7% of patients reported pain only, 12.9% reported swelling only, and 77.4% experienced both pain and swelling. Of the 31 patients initially treated at our clinic (3 initially treated at other institutions), 23 underwent primary resection (74.2%). In the remaining 8 cases (25.8%), the histopathologic diagnosis was first confirmed by biopsy to exclude malignancy.</p><p id="Par16">In total, 21 cases (61.8%) were diagnosed with L-TGCT, while 13 cases (38.2%) were diagnosed with D-TGCT.</p><p id="Par17">The duration of symptoms was significantly shorter in L-TGCT, with a median of 6.0 months, compared to 36 months in D-TGCT (<italic>p</italic>&#x02009;=&#x02009;0.01). Age, BMI, and tumour size did not differ significantly between the two forms of TGCT (<italic>p</italic>&#x02009;=&#x02009;0.356, <italic>p</italic>&#x02009;=&#x02009;0.371, and <italic>p</italic>&#x02009;=&#x02009;0.254, respectively).</p><p id="Par18">Among the 34 cases, 19 (55.9%) were intraarticular, with most (73.7%) originating from the tibiotalar joint. 21.0% originated from the talocalcaneal joint, and one case originated from the proximal interphalangeal joint of the third toe (5.3%). The remaining 15 (44.1%) were extraarticular, primarily affecting the midfoot (46.7%) and forefoot (33.3%). In addition, there were two cases (13.3%) in the hindfoot, and one case (6.7%) in the ankle. Intraarticular involvement was slightly more common in D-TGCT (69.2%) than in L-TGCT (47.6%).</p><p id="Par19">Overall, 33 patients underwent open resection, while one patient underwent arthroscopic synovectomy. In one case, secondary bone grafting from the proximal tibia was performed 14 months after resection of a nodular TGCT in the anterior capsule of the tibiotalar joint to address osseus erosion at the neck of the talus.</p><p id="Par20">The percentage of complete macroscopic tumour resection was 95.2% for L-TGCT, which was significantly higher than 69.2% for D-TGCT (<italic>p</italic>&#x02009;=&#x02009;0.037; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.). Bone involvement was observed in a total of 9 of 34 cases (26.5%), with 19.0% in L-TGCT and 38.5% in D-TGCT (<italic>p</italic>&#x02009;=&#x02009;0.212).</p><p id="Par21">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Macroscopic intraoperative tumour persistence and bone involvement in relation to the type of TGCT</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left" colspan="2">L-TGCT</th><th align="left" colspan="2">D-TGCT</th><th align="left">Total</th></tr><tr><th align="left"/><th align="left"/><th align="left">n</th><th align="left">%</th><th align="left">n</th><th align="left">%</th><th align="left">n</th></tr></thead><tbody><tr><td align="left">Complete tumour removal</td><td align="left">Yes</td><td align="left">20</td><td align="left">95.2%*</td><td align="left">9</td><td align="left">69.2%*</td><td align="left">29</td></tr><tr><td align="left"/><td align="left">Unclear</td><td align="left">1</td><td align="left">4.8%</td><td align="left">4</td><td align="left">30.8%</td><td align="left">5</td></tr><tr><td align="left">Bone involvement</td><td align="left">Yes</td><td align="left">4</td><td align="left">19.0%</td><td align="left">5</td><td align="left">38.5%</td><td align="left">9</td></tr><tr><td align="left"/><td align="left">No</td><td align="left">17</td><td align="left">81.0%</td><td align="left">8</td><td align="left">61.5%</td><td align="left">25</td></tr><tr><td align="left"/><td align="left">Total</td><td align="left">21</td><td align="left">100%</td><td align="left">13</td><td align="left">100%</td><td align="left">34</td></tr></tbody></table></table-wrap>
</p><p id="Par22">During follow-up 2 residuals and 8 local recurrences were observed after a mean time of 9.5 months (SD 6.0 months). In D-TGCT, 4 recurrences were observed in 8 initially tumour-free patients (50.0%) and in L-TGCT, 4 recurrences were observed in 15 initially tumour-free patients (26.7% Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) (<italic>p</italic>&#x02009;=&#x02009;0.263, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>)</p><p id="Par23">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Rate of recurrence in relation to the type of TGCT</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left" colspan="2">D-TGCT</th><th align="left" colspan="2">L-TGCT</th><th align="left">Total</th></tr><tr><th align="left"/><th align="left"/><th align="left">n</th><th align="left">%</th><th align="left">n</th><th align="left">%</th><th align="left">n</th></tr></thead><tbody><tr><td align="left">Recurrence</td><td align="left">Yes</td><td align="left">4</td><td align="left">50.0%</td><td align="left">4</td><td align="left">26.7%</td><td align="left">8</td></tr><tr><td align="left"/><td align="left">No</td><td align="left">4</td><td align="left">50.0%</td><td align="left">11</td><td align="left">73.3%</td><td align="left">15</td></tr><tr><td align="left"/><td align="left">Total</td><td align="left">8</td><td align="left">100%</td><td align="left">15</td><td align="left">100%</td><td align="left">23</td></tr></tbody></table></table-wrap>
</p><p id="Par24">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Case of L-TGCT with complete resection, showing preoperative MRI (sag hemo), preoperative X-ray, intraoperative specimen, and 3-year postoperative MRI confirming no recurrence</p></caption><graphic xlink:href="12885_2025_13921_Fig1_HTML" id="d33e766"/></fig>
</p><p id="Par25">For D-TGCT, recurrences occurred at a mean of 7.0 months (SD 3.2 months; range 3&#x02013;10 months) and for L-TGCT at a mean of 12.0 months (SD 7.5 months; range 5&#x02013;19 months) (<italic>p</italic>&#x02009;=&#x02009;0.287). Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> illustrates this tendency for recurrence to occur earlier with D-TGCT.</p><p id="Par26">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier survival curve for L-TGCT and D-TGCT</p></caption><graphic xlink:href="12885_2025_13921_Fig2_HTML" id="d33e784"/></fig>
</p><p id="Par27">Of the ten residuals and local recurrences, three cases underwent surgical revision after an average of 4.6 years (SD 4.1 years; range 2.0-9.3 years; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) and one case underwent radiation after 23 months. In another case, the tumour board recommended radiation therapy following incomplete primary resection of a D-TGCT, but this was ultimately not performed. In the remaining 6 cases, clinical and radiological follow-up did not show any significant progress.</p><p id="Par28">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Case of D-TGCT with complete resection, showing tumor recurrence on 12-month follow-up MRI, necessitating revision surgery. From left to right: preoperative MRI (T1 sag KM), preoperative X-ray, intraoperative resection (ventral), resected specimen, and postoperative follow-up imaging revealing dorsal recurrence</p></caption><graphic xlink:href="12885_2025_13921_Fig3_HTML" id="d33e799"/></fig>
</p></sec><sec id="Sec10"><title>Discussion</title><p id="Par29">Diagnosing and treating TGCT of the foot and ankle remains challenging due to the relatively small number of patients and the heterogeneous presentation of the disease. In recent years, treatment options beyond surgery, including radiotherapy and systemic therapies have been explored, leading to an ongoing scientific debate [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. However, open surgical resection remains the gold standard, while arthroscopic resection, radiotherapy or targeted systemic therapies may be beneficial in selected patients, for example in recurrent or unresectable cases [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par30">This study represents one of the largest single-centre series of TGCT of the foot and ankle. In accordance with previous studies, the patient population studied exhibited a prevalence of TGCT in the 3rd to 5th decade of life [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. The mean age of patients with D-TGCT was slightly younger than that of patients with L-TGCT, at 32.2 years compared to 37.4 years. This was comparable to the results of a recent meta-analysis by Siegel et al. [<xref ref-type="bibr" rid="CR25">25</xref>], which reported mean ages of 31.2 years and 36.6 years, respectively. The patient population studied demonstrated a female preponderance exceeding 60%, although a significant difference was observed solely within the L-TGCT subgroup (76.2% females vs. 23.8% males). This predisposition for female gender in L-TGCT of the foot and ankle is consistent with previous studies [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>], although it differs from single reports by Cevik et al. [<xref ref-type="bibr" rid="CR41">41</xref>] and Cattelan et al. [<xref ref-type="bibr" rid="CR42">42</xref>], in which 80% and 75% of patients with L-TGCT were male, respectively. Pain and local swelling were more frequently observed in our surgically treated patients compared to a study by Barnett et al. [<xref ref-type="bibr" rid="CR20">20</xref>]. Considering the 2022 consensus paper recommending active surveillance for asymptomatic patients, this may well be considered an appropriate patient selection for surgery [<xref ref-type="bibr" rid="CR27">27</xref>]. It is noteworthy that the time from symptom onset to medical presentation was significantly shorter for L-TGCT with a median of 6 months than for D-TGCT with a median of 36 months. In addition, nearly 10% of the patients studied underwent external surgery and were subsequently surprised by the histopathological result of a TGCT. In light of the potential diagnostic utility of MRI, this work should contribute to a heightened awareness of TGCT, thereby enabling a larger proportion of appropriate preoperative diagnoses in the future [<xref ref-type="bibr" rid="CR43">43</xref>]. For diagnostic certainty, a biopsy was performed prior to resection in 8 of the 31 patients (25.8%). In our management, a biopsy is always performed when the radiological findings do not allow a diagnosis to be made with sufficient certainty and a malignant entity is to be ruled out.</p><p id="Par31">Of the 34 lesions studied, 61.8% were L-TGCT and 38.2% were D-TGCT. This aligns with the most comprehensive retrospective series of TGCT of the foot and ankle, which reported a 69.1% prevalence of L-TGCT and a 30.9% incidence of D-TGCT [<xref ref-type="bibr" rid="CR20">20</xref>]. In contrast, a meta-analysis of TGCT of the foot and ankle revealed that L-TGCT represents only 45.5% and D-TGCT 55.5% of the 382 patients included [<xref ref-type="bibr" rid="CR25">25</xref>]. In our study, L-TGCT was observed intraarticular (<italic>n</italic>&#x02009;=&#x02009;10) and extraarticular (<italic>n</italic>&#x02009;=&#x02009;11) in approximately equal proportions, while D-TGCT was diagnosed intraarticular (<italic>n</italic>&#x02009;=&#x02009;9) twice as often as extraarticular, which is in agreement with the results of Spierenburg et al. [<xref ref-type="bibr" rid="CR30">30</xref>]. The 19 intraarticular lesions were mainly located in the tibiotalar joint (73.3%), while the extraarticular cases were more commonly found in the midfoot (46.7%) and forefoot (33.3%). The observed anatomical distribution pattern is consistent with previous studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par32">Macroscopically complete tumour resection was observed to be significantly less frequent in D-TGCT (69.2%) than in L-TGCT (95.2%), which is consistent with previous studies in other anatomic regions [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, bony erosions were observed with greater frequency in D-TGCT (38.5%) than in L-TGCT (19.0%), although the difference did not reach statistical significance. Palmerini et al. [<xref ref-type="bibr" rid="CR9">9</xref>] demonstrated the clinical importance of macroscopically complete resection associated with superior local control. However, only 16% of the lesions examined in this study affected the foot and ankle. Tsukamoto et al. [<xref ref-type="bibr" rid="CR44">44</xref>] were the first to demonstrate in a series of patients with hindfoot TGCT that macroscopically complete resection was associated with a reduced local recurrence rate. For this reason, given the complex anatomy of the foot and ankle and the proximity of neurovascular structures, our practice favours the open approach. However, studies have reported successful arthroscopic treatment of well-accessible lesions [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par33">Although clinical and radiological follow-up examinations were explicitly recommended, there were no follow-ups in more than one-quarter of cases. Furthermore, in almost two-thirds of cases, follow-up consisted of only one or two examinations, significantly limiting the power of the analysis of recurrence behaviour. The patient population, which is predominantly young and active, may have contributed to the poor adherence to follow-up recommendations. This is due to the benign nature of the tumour and the often slow progression of recurrence and residual disease. Additionally, patients may have expected to self-detect recurrence by symptoms such as swelling or pain without structured radiologic follow-up [<xref ref-type="bibr" rid="CR23">23</xref>]. There is a lack of consensus in the literature regarding the optimal follow-up protocol. For instance, two studies recommended a follow-up period of 5 years with a reduction in the frequency of follow-up examinations over time [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In contrast, other studies employed diagnostic imaging based on clinical symptoms [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] or relied solely on clinical symptoms [<xref ref-type="bibr" rid="CR45">45</xref>]. In their meta-analysis, Siegel et al. [<xref ref-type="bibr" rid="CR25">25</xref>] propose an initial structured clinical and radiological follow-up over 5 years for D-TGCT (baseline after 3 months, semi-annual follow-up for 2 years, and annual follow-up thereafter) and over 3 years for L-TGCT (baseline after 3&#x02013;6 months, and annual follow-up thereafter). They recommend subsequent individualised follow-up depending on clinical symptoms.</p><p id="Par34">The observed recurrence rate was 34.8% overall, with 50.0% for D-TGCT compared to 26.7% for L-TGCT, although this difference did not reach statistical significance. Tsukamoto et al. [<xref ref-type="bibr" rid="CR44">44</xref>] reported a comparable overall recurrence rate of 30.3%. However, our findings should be interpreted cautiously due to the limited sample size and incomplete follow-up data. In the foot and ankle, a recent meta-analysis reported a recurrence rate of 28% for D-TGCT after open resection, and 7% for L-TGCT [<xref ref-type="bibr" rid="CR25">25</xref>]. The higher recurrence rates observed in our study compared to some published literature may reflect selection bias, as symptomatic patients were more likely to attend follow-up appointments. A considerable proportion of patients, potentially those without symptoms, did not comply with recommended follow-up protocols, which represents a significant limitation of our study and may have led to an overestimation of recurrence rates. Furthermore, other studies have reported recurrence rates of 43&#x02013;64% for D-TGCT [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] and 20&#x02013;33% for L-TGCT of the foot and ankle [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par35">In our cohort, the observed time to recurrence for D-TGCT averaged 7.0 months compared to 12.0 months for L-TGCT, though this difference was not statistically significant. These intervals are considerably shorter than those reported by Siegel et al. [<xref ref-type="bibr" rid="CR25">25</xref>], who documented recurrences occurring after an average of 28.3 months for D-TGCT and 44.9 months for L-TGCT [<xref ref-type="bibr" rid="CR25">25</xref>]. Our shorter observed time to recurrence may reflect our limited follow-up duration rather than true biological differences. It is important to note, however, that in both D-TGCT and L-TGCT, more than half of the recurrences are considered to occur within the first 24 months.</p><p id="Par36">Ten cases of residual disease (<italic>n</italic>&#x02009;=&#x02009;2) or local recurrence (<italic>n</italic>&#x02009;=&#x02009;8) were observed. Therapeutic intervention was performed in only four cases. Furthermore, the mean time between primary resection and recurrence diagnosis was 1.0 years, significantly shorter than the time between primary resection and revision surgery, which was 4.6 years. These two observations demonstrate that TGCT often exhibits no or slow morphological and clinical progression, and that nonoperative management with symptomatic surveillance is a viable option. Barnett et al. [<xref ref-type="bibr" rid="CR20">20</xref>] reported that more than three-quarters of 13 patients treated nonoperatively exhibited erosions but did not develop clinical symptoms. This is consistent with the observation that only 37&#x02013;55% of cases after incomplete synovectomies develop recurrence of symptoms, and several studies have reported a regular lack of clinical and radiological progression [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Consequently, it is possible to achieve disease stabilisation, particularly when surgical resection is associated with significant loss of function, as TGCT is very rarely associated with non-local risk [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par37">Moreover, as TGCT is caused by an upregulation of the CSF1 gene and the recruitment of CSF1R-dependent inflammatory cells, tyrosine kinase inhibitors targeting the CSF1 receptor have been used to treat TGCT when surgery is not an option [<xref ref-type="bibr" rid="CR49">49</xref>]. In 2019, the FDA approved pexidartinib for the systemic treatment of those adults with severe morbidity and functional limitations [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. In a real-world study, Lin et al. [<xref ref-type="bibr" rid="CR52">52</xref>] reported clinically significant improvements in overall symptoms and physical function, as well as reduced use of medications and physical therapy during treatment. However, since its approval, only 0.4% of patients with TGCT in the US have been treated with pexidartinib [<xref ref-type="bibr" rid="CR53">53</xref>] and other systemic therapies have been studied but are not specifically approved for the treatment of TGCT, such as anti-cytokine biologics and RANKL inhibitors [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par38">It is important to note that this study has several limitations. First, clinical data were collected from operative reports and correspondence, meaning that the quality of documentation could potentially affect the reliability of the results. Second, measuring the size of TGCT is challenging due to the complex morphology and heterogeneity of preoperative MRI images, which may have influenced the validity of this parameter. Third, assessing the completeness of resection in benign tumors is difficult as there is no histopathological confirmation of the resection status. As such, we relied on surgical reports to evaluate the quality of resection. Fourth, the overall number of patients and the number of patients with follow-up were relatively small, which limits the statistical power of the analysis. Some recurrences and recurrence-free courses were not identified due to the absence of routine MRI follow-up for all cases. Fifth, the retrospective nature of the study and the unstructured follow-up protocol introduce potential biases in our findings, and a comprehensive evaluation of complications and functional outcomes was not possible. Additionally, the single-center design limits the generalizability of our results to other clinical settings and patient populations. Nevertheless, this study provides valuable new insights into the understanding and management of TGCT of the foot and ankle.</p></sec><sec id="Sec11"><title>Conclusions</title><p id="Par39">L-TGCTs are characterized by a shorter latency period from symptom onset to clinical presentation and exhibit a higher prevalence in females. Additionally, these tumors have a greater likelihood of complete resection. In contrast, our findings suggest that D-TGCTs may be more frequently associated with bone involvement and a higher risk of recurrence compared to L-TGCTs, although these differences did not reach statistical significance, likely due to the limited sample size. Intraarticular TGCTs predominantly affect the hindfoot, while extraarticular TGCTs are more commonly observed in the forefoot and midfoot. MRI generally provides an accurate diagnostic tool; however, in cases with ambiguous findings, biopsy remains essential for histological confirmation. Our results indicate that orthopaedic surgeons should carefully consider the balance between the extent of surgical resection and the preservation of functional outcomes. Despite some cases of residual or recurrent disease, stable clinical results may still be achievable, based on our limited follow-up.</p></sec></body><back><fn-group><fn><p>The original version of this article was revised: The author, Christian Scheele, was mistakenly displayed twice in the author group.</p></fn><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Author Contributions: Conceptualization, F.L., U.L., and N.H.; methodology, C.K. and N.H.; software, C.S.; validation, F.L., S.B., and R.v.E.-R.; collection, analysis, and interpretation of patient data, C.S.; resources and data curation, F.L.; writing&#x02014;original draft preparation, C.S.; writing&#x02014;review and editing, C.S., D.D., F.L., and N.H.; visualization, C.S.; supervision, C.K., R.v.E.-R.; project administration, F.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p><p>No funding was obtained.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Availability of data and material: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par40">Approval of local ethics committee (TU Munich) was obtained (no. 2023-103-S-KH). All patients signed an informed consent form.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par41">All authors agreed to publish.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par42">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>LB</given-names></name><name><surname>Ho</surname><given-names>YY</given-names></name><name><surname>Malawer</surname><given-names>MM</given-names></name></person-group><article-title>Tumors of the foot and ankle: experience with 153 cases</article-title><source>Foot Ankle Int</source><year>2009</year><volume>30</volume><issue>9</issue><fpage>836</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19755066</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Chou LB, Ho YY, Malawer MM. Tumors of the foot and ankle: experience with 153 cases. Foot Ankle Int. 2009;30(9):836&#x02013;41.<pub-id pub-id-type="pmid">19755066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Toepfer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Distribution patterns of foot and ankle tumors: a university tumor Institute experience</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>735</fpage><pub-id pub-id-type="pmid">30001718</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Toepfer A, et al. Distribution patterns of foot and ankle tumors: a university tumor Institute experience. BMC Cancer. 2018;18(1):735.<pub-id pub-id-type="pmid">30001718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Mendenhall</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Pigmented villonodular synovitis</article-title><source>Am J Clin Oncol</source><year>2006</year><volume>29</volume><issue>6</issue><fpage>548</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17148989</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mendenhall WM, et al. Pigmented villonodular synovitis. Am J Clin Oncol. 2006;29(6):548&#x02013;50.<pub-id pub-id-type="pmid">17148989</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Szendroi</surname><given-names>M</given-names></name><name><surname>Deodhar</surname><given-names>A</given-names></name></person-group><article-title>Synovial neoformations and tumours</article-title><source>Baillieres Best Pract Res Clin Rheumatol</source><year>2000</year><volume>14</volume><issue>2</issue><fpage>363</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">10925750</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Szendroi M, Deodhar A. Synovial neoformations and tumours. Baillieres Best Pract Res Clin Rheumatol. 2000;14(2):363&#x02013;83.<pub-id pub-id-type="pmid">10925750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukui</surname><given-names>K</given-names></name><etal/></person-group><article-title>Localized pigmented villonodular synovitis of the hip: sudden-onset pain caused by torsion of the tumor pedicle</article-title><source>Case Rep Orthop</source><year>2013</year><volume>2013</volume><fpage>p862935</fpage></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fukui K, et al. Localized pigmented villonodular synovitis of the hip: sudden-onset pain caused by torsion of the tumor pedicle. Case Rep Orthop. 2013;2013:p862935.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Gouin</surname><given-names>F</given-names></name><name><surname>Noailles</surname><given-names>T</given-names></name></person-group><article-title>Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)</article-title><source>Orthop Traumatol Surg Res</source><year>2017</year><volume>103</volume><issue>1S</issue><fpage>S91</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">28057477</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop Traumatol Surg Res. 2017;103(1S):S91&#x02013;7.<pub-id pub-id-type="pmid">28057477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>BW</given-names></name><name><surname>Masi</surname><given-names>AT</given-names></name></person-group><article-title>Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review</article-title><source>Med (Baltim)</source><year>1980</year><volume>59</volume><issue>3</issue><fpage>223</fpage><lpage>38</lpage></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Myers BW, Masi AT. Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review. Med (Baltim). 1980;59(3):223&#x02013;38.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Pigmented villonodular synovitis of the knee: A retrospective analysis of 214 cases at a UK tertiary referral centre</article-title><source>Knee</source><year>2017</year><volume>24</volume><issue>4</issue><fpage>808</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">28442184</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Patel KH, et al. Pigmented villonodular synovitis of the knee: A retrospective analysis of 214 cases at a UK tertiary referral centre. Knee. 2017;24(4):808&#x02013;15.<pub-id pub-id-type="pmid">28442184</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Palmerini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors</article-title><source>Eur J Cancer</source><year>2015</year><volume>51</volume><issue>2</issue><fpage>210</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25465190</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Palmerini E, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer. 2015;51(2):210&#x02013;7.<pub-id pub-id-type="pmid">25465190</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Mastboom</surname><given-names>MJL</given-names></name><etal/></person-group><article-title>Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study</article-title><source>Lancet Oncol</source><year>2019</year><volume>20</volume><issue>6</issue><fpage>877</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">31029509</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Mastboom MJL, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019;20(6):877&#x02013;86.<pub-id pub-id-type="pmid">31029509</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>de Visser</surname><given-names>E</given-names></name><etal/></person-group><article-title>Diffuse and localized pigmented villonodular synovitis: evaluation of treatment of 38 patients</article-title><source>Arch Orthop Trauma Surg</source><year>1999</year><volume>119</volume><issue>7&#x02013;8</issue><fpage>401</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10613228</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">de Visser E, et al. Diffuse and localized pigmented villonodular synovitis: evaluation of treatment of 38 patients. Arch Orthop Trauma Surg. 1999;119(7&#x02013;8):401&#x02013;4.<pub-id pub-id-type="pmid">10613228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Granowitz</surname><given-names>SP</given-names></name><name><surname>Mankin</surname><given-names>HJ</given-names></name></person-group><article-title>Localized pigmented villonodular synovitis of the knee. Report of five cases</article-title><source>J Bone Joint Surg Am</source><year>1967</year><volume>49</volume><issue>1</issue><fpage>122</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">6015755</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Granowitz SP, Mankin HJ. Localized pigmented villonodular synovitis of the knee. Report of five cases. J Bone Joint Surg Am. 1967;49(1):122&#x02013;8.<pub-id pub-id-type="pmid">6015755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Granowitz SP, D&#x02019;Antonio J, Mankin HL. The pathogenesis and long-term end results of pigmented villonodular synovitis. Clin Orthop Relat Res, 1976(114): pp. 335&#x02013;51.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Byers</surname><given-names>PD</given-names></name><etal/></person-group><article-title>The diagnosis and treatment of pigmented villonodular synovitis</article-title><source>J Bone Joint Surg Br</source><year>1968</year><volume>50</volume><issue>2</issue><fpage>290</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">4297226</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Byers PD, et al. The diagnosis and treatment of pigmented villonodular synovitis. J Bone Joint Surg Br. 1968;50(2):290&#x02013;305.<pub-id pub-id-type="pmid">4297226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>AS</given-names></name><name><surname>Vigorita</surname><given-names>VJ</given-names></name></person-group><article-title>Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases</article-title><source>J Bone Joint Surg Am</source><year>1984</year><volume>66</volume><issue>1</issue><fpage>76</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">6317696</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rao AS, Vigorita VJ. Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases. J Bone Joint Surg Am. 1984;66(1):76&#x02013;94.<pub-id pub-id-type="pmid">6317696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Dines</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Long-term follow-up of surgically treated localized pigmented villonodular synovitis of the knee</article-title><source>Arthroscopy</source><year>2007</year><volume>23</volume><issue>9</issue><fpage>930</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17868831</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Dines JS, et al. Long-term follow-up of surgically treated localized pigmented villonodular synovitis of the knee. Arthroscopy. 2007;23(9):930&#x02013;7.<pub-id pub-id-type="pmid">17868831</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ogilvie-Harris</surname><given-names>DJ</given-names></name><name><surname>McLean</surname><given-names>J</given-names></name><name><surname>Zarnett</surname><given-names>ME</given-names></name></person-group><article-title>Pigmented villonodular synovitis of the knee. The results of total arthroscopic synovectomy, partial, arthroscopic synovectomy, and arthroscopic local excision</article-title><source>J Bone Joint Surg Am</source><year>1992</year><volume>74</volume><issue>1</issue><fpage>119</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">1463472</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ogilvie-Harris DJ, McLean J, Zarnett ME. Pigmented villonodular synovitis of the knee. The results of total arthroscopic synovectomy, partial, arthroscopic synovectomy, and arthroscopic local excision. J Bone Joint Surg Am. 1992;74(1):119&#x02013;23.<pub-id pub-id-type="pmid">1463472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ottaviani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature</article-title><source>Semin Arthritis Rheum</source><year>2011</year><volume>40</volume><issue>6</issue><fpage>539</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">20884045</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ottaviani S, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011;40(6):539&#x02013;46.<pub-id pub-id-type="pmid">20884045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Cheng</surname><given-names>EY</given-names></name></person-group><article-title>Outcomes after excision of pigmented villonodular synovitis of the knee</article-title><source>Clin Orthop Relat Res</source><year>2009</year><volume>467</volume><issue>11</issue><fpage>2852</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19543865</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Sharma V, Cheng EY. Outcomes after excision of pigmented villonodular synovitis of the knee. Clin Orthop Relat Res. 2009;467(11):2852&#x02013;8.<pub-id pub-id-type="pmid">19543865</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Barnett JR, et al. Outcomes of tenosynovial giant cell tumor of the foot and ankle. Foot Ankle Int; 2023. p. 10711007231189491.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor</article-title><source>Sarcoma</source><year>2010</year><volume>2010</volume><fpage>p174528</fpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Cheng H, et al. Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma. 2010;2010:p174528.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Adelani</surname><given-names>MA</given-names></name><name><surname>Wupperman</surname><given-names>RM</given-names></name><name><surname>Holt</surname><given-names>GE</given-names></name></person-group><article-title>Benign synovial disorders</article-title><source>J Am Acad Orthop Surg</source><year>2008</year><volume>16</volume><issue>5</issue><fpage>268</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">18460687</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Adelani MA, Wupperman RM, Holt GE. Benign synovial disorders. J Am Acad Orthop Surg. 2008;16(5):268&#x02013;75.<pub-id pub-id-type="pmid">18460687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoni</surname><given-names>F</given-names></name><etal/></person-group><article-title>Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis)</article-title><source>Am J Surg Pathol</source><year>1997</year><volume>21</volume><issue>2</issue><fpage>153</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9042281</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Bertoni F, et al. Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Am J Surg Pathol. 1997;21(2):153&#x02013;63.<pub-id pub-id-type="pmid">9042281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JH</given-names></name><name><surname>Pugh</surname><given-names>DG</given-names></name></person-group><article-title>Roentgenographic aspects of articular pigmented villonodular synovitis</article-title><source>Am J Roentgenol Radium Ther Nucl Med</source><year>1962</year><volume>87</volume><fpage>1146</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">13914294</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Smith JH, Pugh DG. Roentgenographic aspects of articular pigmented villonodular synovitis. Am J Roentgenol Radium Ther Nucl Med. 1962;87:1146&#x02013;56.<pub-id pub-id-type="pmid">13914294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Treatment, recurrence rates and follow-up of tenosynovial giant cell tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><issue>12</issue><fpage>e0260795</fpage><pub-id pub-id-type="pmid">34855875</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Siegel M, et al. Treatment, recurrence rates and follow-up of tenosynovial giant cell tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis. PLoS ONE. 2021;16(12):e0260795.<pub-id pub-id-type="pmid">34855875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Tap</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10197</issue><fpage>478</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">31229240</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Tap WD, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478&#x02013;87.<pub-id pub-id-type="pmid">31229240</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Stacchiotti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts</article-title><source>Cancer Treat Rev</source><year>2023</year><volume>112</volume><fpage>102491</fpage><pub-id pub-id-type="pmid">36502615</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Stacchiotti S, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491.<pub-id pub-id-type="pmid">36502615</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Results and recurrence of pigmented villonodular synovitis of the ankle: does diffuse PVNS with extra-articular extension tend to recur more often?</article-title><source>Knee Surg Sports Traumatol Arthrosc</source><year>2018</year><volume>26</volume><issue>10</issue><fpage>3118</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">28389877</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Guo Q, et al. Results and recurrence of pigmented villonodular synovitis of the ankle: does diffuse PVNS with extra-articular extension tend to recur more often? Knee Surg Sports Traumatol Arthrosc. 2018;26(10):3118&#x02013;23.<pub-id pub-id-type="pmid">28389877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Cassier</surname><given-names>PA</given-names></name><etal/></person-group><article-title>CSF1R Inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>8</issue><fpage>949</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">26179200</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Cassier PA, et al. CSF1R Inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949&#x02013;56.<pub-id pub-id-type="pmid">26179200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Spierenburg</surname><given-names>G</given-names></name><etal/></person-group><article-title>Management of tenosynovial giant cell tumour of the foot and ankle</article-title><source>Bone Joint J</source><year>2021</year><volume>103&#x02013;B</volume><issue>4</issue><fpage>788</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">33789469</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Spierenburg G, et al. Management of tenosynovial giant cell tumour of the foot and ankle. Bone Joint J. 2021;103&#x02013;B(4):788&#x02013;94.<pub-id pub-id-type="pmid">33789469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Fraser EJ et al. Tenosynovial Giant-Cell tumors of the foot and ankle: A critical analysis review. JBJS Rev, 2017. 5(1).</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Healey</surname><given-names>JH</given-names></name><name><surname>Bernthal</surname><given-names>NM</given-names></name><name><surname>van de Sande</surname><given-names>M</given-names></name></person-group><article-title>Management of tenosynovial giant cell tumor: A neoplastic and inflammatory disease</article-title><source>J Am Acad Orthop Surg Glob Res Rev</source><year>2020</year><volume>4</volume><issue>11</issue><fpage>e2000028</fpage></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Healey JH, Bernthal NM, van de Sande M. Management of tenosynovial giant cell tumor: A neoplastic and inflammatory disease. J Am Acad Orthop Surg Glob Res Rev. 2020;4(11):e2000028.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Cannarile MA et al. <italic>Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.</italic> J Immunother Cancer, 2017. 5(1): p. 53.</mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="book"><person-group person-group-type="author"><name><surname>De Saint Aubain Somerhausen</surname><given-names>N</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fletcher</surname><given-names>CDM</given-names></name><name><surname>Bridge</surname><given-names>JA</given-names></name><name><surname>Hogendoorn</surname><given-names>PCW</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name></person-group><article-title>Tenosynovial giant cell tumour</article-title><source>WHO classification of tumours of soft-tissue and bone</source><year>2013</year><edition>4</edition><publisher-loc>Lyon</publisher-loc><publisher-name>IARC</publisher-name><fpage>100</fpage><lpage>3</lpage></element-citation><mixed-citation id="mc-CR34" publication-type="book">De Saint Aubain Somerhausen N. Tenosynovial giant cell tumour. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft-tissue and bone. 4th ed. Lyon: IARC; 2013. pp. 100&#x02013;3.</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Surgical treatment for diffused-type giant cell tumor (pigmented villonodular synovitis) about the ankle joint</article-title><source>BMC Musculoskelet Disord</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>450</fpage><pub-id pub-id-type="pmid">29137617</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Li X, et al. Surgical treatment for diffused-type giant cell tumor (pigmented villonodular synovitis) about the ankle joint. BMC Musculoskelet Disord. 2017;18(1):450.<pub-id pub-id-type="pmid">29137617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Bisbinas</surname><given-names>I</given-names></name><name><surname>De Silva</surname><given-names>U</given-names></name><name><surname>Grimer</surname><given-names>RJ</given-names></name></person-group><article-title>Pigmented villonodular synovitis of the foot and ankle: a 12-year experience from a tertiary orthopedic oncology unit</article-title><source>J Foot Ankle Surg</source><year>2004</year><volume>43</volume><issue>6</issue><fpage>407</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15605054</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Bisbinas I, De Silva U, Grimer RJ. Pigmented villonodular synovitis of the foot and ankle: a 12-year experience from a tertiary orthopedic oncology unit. J Foot Ankle Surg. 2004;43(6):407&#x02013;11.<pub-id pub-id-type="pmid">15605054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Brien</surname><given-names>EW</given-names></name><name><surname>Sacoman</surname><given-names>DM</given-names></name><name><surname>Mirra</surname><given-names>JM</given-names></name></person-group><article-title>Pigmented villonodular synovitis of the foot and ankle</article-title><source>Foot Ankle Int</source><year>2004</year><volume>25</volume><issue>12</issue><fpage>908</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15680105</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Brien EW, Sacoman DM, Mirra JM. Pigmented villonodular synovitis of the foot and ankle. Foot Ankle Int. 2004;25(12):908&#x02013;13.<pub-id pub-id-type="pmid">15680105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Korim</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Clinical and oncological outcomes after surgical excision of pigmented villonodular synovitis at the foot and ankle</article-title><source>Foot Ankle Surg</source><year>2014</year><volume>20</volume><issue>2</issue><fpage>130</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">24796833</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Korim MT, et al. Clinical and oncological outcomes after surgical excision of pigmented villonodular synovitis at the foot and ankle. Foot Ankle Surg. 2014;20(2):130&#x02013;4.<pub-id pub-id-type="pmid">24796833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Giant cell tumor of the tendon sheath in the foot and ankle: case series and review of the literature</article-title><source>J Foot Ankle Surg</source><year>2013</year><volume>52</volume><issue>1</issue><fpage>24</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23085383</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zhang Y, et al. Giant cell tumor of the tendon sheath in the foot and ankle: case series and review of the literature. J Foot Ankle Surg. 2013;52(1):24&#x02013;7.<pub-id pub-id-type="pmid">23085383</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>H</given-names></name><name><surname>Jane</surname><given-names>MJ</given-names></name><name><surname>Reid</surname><given-names>R</given-names></name></person-group><article-title>Pigmented villonodular synovitis of the foot and ankle: Forty years of experience from the Scottish bone tumor registry</article-title><source>J Foot Ankle Surg</source><year>2006</year><volume>45</volume><issue>5</issue><fpage>329</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16949531</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Sharma H, Jane MJ, Reid R. Pigmented villonodular synovitis of the foot and ankle: Forty years of experience from the Scottish bone tumor registry. J Foot Ankle Surg. 2006;45(5):329&#x02013;36.<pub-id pub-id-type="pmid">16949531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Cevik</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Tenosynovial giant cell tumor in the foot and ankle</article-title><source>Foot Ankle Surg</source><year>2020</year><volume>26</volume><issue>6</issue><fpage>712</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">31526689</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Cevik HB, et al. Tenosynovial giant cell tumor in the foot and ankle. Foot Ankle Surg. 2020;26(6):712&#x02013;6.<pub-id pub-id-type="pmid">31526689</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Cattelan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Villonodular synovitis of the ankle. Analysis of the risk of recurrence</article-title><source>Orthop Traumatol Surg Res</source><year>2016</year><volume>102</volume><issue>5</issue><fpage>639</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">27197681</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Cattelan M, et al. Villonodular synovitis of the ankle. Analysis of the risk of recurrence. Orthop Traumatol Surg Res. 2016;102(5):639&#x02013;44.<pub-id pub-id-type="pmid">27197681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Imaging of giant cell tumour of the tendon sheath</article-title><source>Radiol Med</source><year>2010</year><volume>115</volume><issue>1</issue><fpage>141</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20077044</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Wan JM, et al. Imaging of giant cell tumour of the tendon sheath. Radiol Med. 2010;115(1):141&#x02013;51.<pub-id pub-id-type="pmid">20077044</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incomplete resection increases the risk of local recurrence and negatively affects functional outcome in patients with tenosynovial giant cell tumor of the hindfoot</article-title><source>Foot Ankle Surg</source><year>2020</year><volume>26</volume><issue>7</issue><fpage>822</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">31839476</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Tsukamoto S, et al. Incomplete resection increases the risk of local recurrence and negatively affects functional outcome in patients with tenosynovial giant cell tumor of the hindfoot. Foot Ankle Surg. 2020;26(7):822&#x02013;7.<pub-id pub-id-type="pmid">31839476</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Rochwerger</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pigmented villonodular synovitis of the foot and ankle: a report of eight cases</article-title><source>Foot Ankle Int</source><year>1999</year><volume>20</volume><issue>9</issue><fpage>587</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">10509687</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Rochwerger A, et al. Pigmented villonodular synovitis of the foot and ankle: a report of eight cases. Foot Ankle Int. 1999;20(9):587&#x02013;90.<pub-id pub-id-type="pmid">10509687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Diffuse pigmented villonodular synovitis (diffuse-type giant cell tumour) of the foot and ankle</article-title><source>Bone Joint J</source><year>2013</year><volume>95&#x02013;B</volume><issue>3</issue><fpage>384</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">23450025</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Stevenson JD, et al. Diffuse pigmented villonodular synovitis (diffuse-type giant cell tumour) of the foot and ankle. Bone Joint J. 2013;95&#x02013;B(3):384&#x02013;90.<pub-id pub-id-type="pmid">23450025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Klompmaker</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pigmented villonodular synovitis</article-title><source>Arch Orthop Trauma Surg</source><year>1990</year><volume>109</volume><issue>4</issue><fpage>205</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">2383449</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Klompmaker J, et al. Pigmented villonodular synovitis. Arch Orthop Trauma Surg. 1990;109(4):205&#x02013;10.<pub-id pub-id-type="pmid">2383449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>KS</given-names></name><name><surname>Ko</surname><given-names>KR</given-names></name></person-group><article-title>Surgical outcomes after excision of pigmented villonodular synovitis localized to the ankle and hindfoot without adjuvant therapy</article-title><source>J Foot Ankle Surg</source><year>2015</year><volume>54</volume><issue>2</issue><fpage>160</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">25618808</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sung KS, Ko KR. Surgical outcomes after excision of pigmented villonodular synovitis localized to the ankle and hindfoot without adjuvant therapy. J Foot Ankle Surg. 2015;54(2):160&#x02013;3.<pub-id pub-id-type="pmid">25618808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Tap</surname><given-names>WD</given-names></name><etal/></person-group><article-title>The MOTION study: a randomized, phase III study of Vimseltinib for the treatment of tenosynovial giant cell tumor</article-title><source>Future Oncol</source><year>2024</year><volume>20</volume><issue>10</issue><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">37593881</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Tap WD, et al. The MOTION study: a randomized, phase III study of Vimseltinib for the treatment of tenosynovial giant cell tumor. Future Oncol. 2024;20(10):593&#x02013;601.<pub-id pub-id-type="pmid">37593881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Tap</surname><given-names>W</given-names></name></person-group><article-title>ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT)</article-title><source>Future Oncol</source><year>2020</year><volume>16</volume><issue>25</issue><fpage>1875</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32755241</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Tap W. ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 2020;16(25):1875&#x02013;8.<pub-id pub-id-type="pmid">32755241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Monestime</surname><given-names>S</given-names></name><name><surname>Lazaridis</surname><given-names>D</given-names></name></person-group><article-title>Pexidartinib (TURALIO): the first FDA-Indicated systemic treatment for tenosynovial giant cell tumor</article-title><source>Drugs R D</source><year>2020</year><volume>20</volume><issue>3</issue><fpage>189</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">32617868</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Monestime S, Lazaridis D. Pexidartinib (TURALIO): the first FDA-Indicated systemic treatment for tenosynovial giant cell tumor. Drugs R D. 2020;20(3):189&#x02013;95.<pub-id pub-id-type="pmid">32617868</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Real-World patient experience of pexidartinib for tenosynovial Giant-Cell tumor</article-title><source>Oncologist</source><year>2024</year><volume>29</volume><issue>4</issue><fpage>e535</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">37874926</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Lin F, et al. Real-World patient experience of pexidartinib for tenosynovial Giant-Cell tumor. Oncologist. 2024;29(4):e535&#x02013;43.<pub-id pub-id-type="pmid">37874926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Dharmani C, et al. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA. Future Oncol; 2024.</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>M</given-names></name><name><surname>Farese</surname><given-names>H</given-names></name><name><surname>Miossec</surname><given-names>P</given-names></name></person-group><article-title>Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>820046</fpage><pub-id pub-id-type="pmid">35265077</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Robert M, Farese H, Miossec P. Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features. Front Immunol. 2022;13:820046.<pub-id pub-id-type="pmid">35265077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Huang</surname><given-names>HY</given-names></name></person-group><article-title>Soft tissue special issue: giant Cell-Rich lesions of the head and neck region</article-title><source>Head Neck Pathol</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">31950466</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Lee JC, Huang HY. Soft tissue special issue: giant Cell-Rich lesions of the head and neck region. Head Neck Pathol. 2020;14(1):97&#x02013;108.<pub-id pub-id-type="pmid">31950466</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>